Guildford, United Kingdom
Guildford, United Kingdom

Time filter

Source Type

News Article | November 8, 2016
Site: www.newsmaker.com.au

Global Stem Cell Banking Market is accounted for $1.42 billion in 2015 and is expected to reach $4.58 billion by 2022 growing at a CAGR of 18.2% during the forecast period. Growing number of newborns, increasing usage of stem cells in disorder treatment and rising disposable income are some of the factors fueling the market growth. However, huge operating price and regulatory changes are some of the factors hampering the market. Rising awareness about potential use of cord tissue and the automation of procedures are creating opportunities for vendors in the market. Some of the key players in Stem Cell Banking market include Cordvida, International Stem Cell Corporation, BrainStorm Cell Therapeutics, ReeLabs, Gamida Cell, Cryo Stemcell, Medistem Inc, CordCare, RMS Regrow, Cellular Dynamics International, Arteriocyte, ReNeuron Group, Jeevan Blood Bank Research Center, RhinoCyte, Inc., Cytori Therapeutics, Inc. and StemOne Biologicals. Regions Covered:  • North America  o US  o Canada  o Mexico  • Europe  o Germany  o France  o Italy  o UK  o Spain  o Rest of Europe  • Asia Pacific  o Japan  o China  o India  o Australia  o New Zealand  o Rest of Asia Pacific  • Rest of the World  o Middle East  o Brazil  o Argentina  o South Africa  o Egypt What our report offers:  - Market share assessments for the regional and country level segments  - Market share analysis of the top industry players  - Strategic recommendations for the new entrants  - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets  - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)  - Strategic recommendations in key business segments based on the market estimations  - Competitive landscaping mapping the key common trends  - Company profiling with detailed strategies, financials, and recent developments  - Supply chain trends mapping the latest technological advancements About Us Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.


News Article | November 8, 2016
Site: marketersmedia.com

— Global Stem Cell Banking Market is accounted for $1.42 billion in 2015 and is expected to reach $4.58 billion by 2022 growing at a CAGR of 18.2% during the forecast period. Growing number of newborns, increasing usage of stem cells in disorder treatment and rising disposable income are some of the factors fueling the market growth. However, huge operating price and regulatory changes are some of the factors hampering the market. Rising awareness about potential use of cord tissue and the automation of procedures are creating opportunities for vendors in the market. Some of the key players in Stem Cell Banking market include Cordvida, International Stem Cell Corporation, BrainStorm Cell Therapeutics, ReeLabs, Gamida Cell, Cryo Stemcell, Medistem Inc, CordCare, RMS Regrow, Cellular Dynamics International, Arteriocyte, ReNeuron Group, Jeevan Blood Bank Research Center, RhinoCyte, Inc., Cytori Therapeutics, Inc. and StemOne Biologicals. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Us Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. For more information, please visit https://www.wiseguyreports.com/reports/731622-stem-cell-banking-global-market-outlook-2016-2022


News Article | December 10, 2016
Site: marketersmedia.com

— Stroke Pipeline Market Companies Involved in Therapeutics Development are AB Science SA, Acticor Biotech, ActiveSite Pharmaceuticals Inc, Addex Therapeutics Ltd, advanceCor GmbH, Affibody AB, Amarantus Bioscience Holdings Inc, Anavex Life Sciences Corp, Angion Biomedica Corp, Antoxis Ltd, APT Therapeutics, Inc., ArmaGen Inc, Asterias Biotherapeutics, Inc., AstraZeneca Plc, Athersys Inc, Bayer AG, Bioasis Technologies Inc, Biogen Inc, Boehringer Ingelheim GmbH, Cardax Inc, Cellular Biomedicine Group Inc, CHA Bio & Diostech Co Ltd, ContraVir Pharmaceuticals Inc, CSPC Pharmaceutical Group Limited, D-Pharm Ltd, Daiichi Sankyo Company Ltd, DiaMedica Inc, Diffusion Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Fina Biotech, Genervon Biopharmaceuticals LLC, Glialogix Inc, Glucox Biotech AB, Green Cross Corp, Huons Co Ltd, International Stem Cell Corp, Jeil Pharmaceutical Co Ltd, JN-International Medical Corp, Laboratoires Pierre Fabre SA, LegoChem Biosciences Inc, Les Laboratoires Servier SAS, Living Cell Technologies Ltd, Lumosa Therapeutics Co Ltd, M et P Pharma AG, Magnus Life Ltd, Mapreg SAS, Mast Therapeutics Inc, Medestea Research & Production SpA, Mitochon Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corp, Neuralstem Inc, Neuren Pharmaceuticals Ltd, Neurofx Inc, Neuronax SAS, Neurotec Pharma SL, NeuroVive Pharmaceutical AB, New Haven Pharmaceuticals, Inc., New World Laboratories Inc, NoNO Inc, NuvOx Pharma LLC, Omeros Corp, Panacea Pharmaceuticals Inc, PharmatrophiX, Inc., Pharmaxis Ltd, Pharmicell Co Ltd, Phoenix Biotechnology Inc, Phylogica Ltd, PhytoHealth Corp, Pluristem Therapeutics Inc, Primary Peptides, Inc., Q Therapeutics Inc, QR Pharma Inc, ReCyte Therapeutics Inc, Regenera Pharma Ltd, RegeneRx Biopharmaceuticals Inc, Remedy Pharmaceuticals Inc, ReNeuron Group Plc, SanBio Inc, Saneron CCEL Therapeutics Inc, Shin Poong PharmCo Ltd, Simcere Pharmaceutical Group, Stemedica Cell Technologies Inc, SynZyme Technologies LLC, Targazyme Inc, The International Biotechnology Center (IBC) Generium, TikoMed AB, vasopharm GmbH, Verseon Corp, Vicore Pharma AB, Virogenomics BioDevelopment Inc, WhanIn Pharmaceutical Co Ltd and Zocere Inc. This research provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=774104 The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 10, 21, 14, 1, 89 and 11 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 35 and 4 molecules, respectively. Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Buy a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=774104 • The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular). • The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/774104-stroke-pipeline-review-h2-2016.html


— Growing number of newborns, increasing usage of stem cells in disorder treatment and rising disposable income are some of the factors fueling the market growth. However, huge operating price and regulatory changes are some of the factors hampering the market. Rising awareness about potential use of cord tissue and the automation of procedures are creating opportunities for vendors in the market. Some of the key players in Stem Cell Banking market include Cordvida, International Stem Cell Corporation, BrainStorm Cell Therapeutics, ReeLabs, Gamida Cell, Cryo Stemcell, Medistem Inc, CordCare, RMS Regrow, Cellular Dynamics International, Arteriocyte, ReNeuron Group, Jeevan Blood Bank Research Center, RhinoCyte, Inc., Cytori Therapeutics, Inc. and StemOne Biologicals. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/


News Article | November 23, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Stem Cell Banking Market is accounted for $1.42 billion in 2015 and is expected to reach $4.58 billion by 2022 growing at a CAGR of 18.2% during the forecast period. Growing number of newborns, increasing usage of stem cells in disorder treatment and rising disposable income are some of the factors fueling the market growth. However, huge operating price and regulatory changes are some of the factors hampering the market. Rising awareness about potential use of cord tissue and the automation of procedures are creating opportunities for vendors in the market. Some of the key players in Stem Cell Banking market include Cordvida, International Stem Cell Corporation, BrainStorm Cell Therapeutics, ReeLabs, Gamida Cell, Cryo Stemcell, Medistem Inc, CordCare, RMS Regrow, Cellular Dynamics International, Arteriocyte, ReNeuron Group, Jeevan Blood Bank Research Center, RhinoCyte, Inc., Cytori Therapeutics, Inc. and StemOne Biologicals. • Leukemia • Cerebral Palsy • Autism • Thalassemia • Diabetes • Other Applications Bank Types Covered: • Cord Tissue • Cord Blood  Service Types Covered: • Analysis • Collection & Transportation • Storage • Processing Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain o Rest of Europe       • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific • Rest of the World o Middle East o Brazil       o Argentina        o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


Hassani Z.,King's College London | O'Reilly J.,King's College London | Pearse Y.,King's College London | Stroemer P.,ReNeuron Group | And 4 more authors.
PLoS ONE | Year: 2012

Main Objectives: Stem cell transplantation is to date one of the most promising therapies for chronic ischemic stroke. The human conditionally immortalised neural stem cell line, CTX0E03, has demonstrable efficacy in a rodent model of stroke and is currently in clinical trials. Nonetheless, the mechanisms by which it promotes brain repair are not fully characterised. This study investigated the cellular events occurring after CTX0E03 transplantation in the brains of rats that underwent ischemic stroke. Methods: We focused on the endogenous proliferative activity of the host brain in response to cell transplantation and determined the identity of the proliferating cells using markers for young neurons (doublecortin, Dcx) and microglia (CD11b). So as to determine the chronology of events occurring post-transplantation, we analysed the engrafted brains one week and four weeks post-transplantation. Results: We observed a significantly greater endogenous proliferation in the striatum of ischemic brains receiving a CTX0E03 graft compared to vehicle-treated ischemic brains. A significant proportion of these proliferative cells were found to be Dcx+ striatal neuroblasts. Further, we describe an enhanced immune response after CTX0E03 engraftment, as shown by a significant increase of proliferating CD11b+ microglial cells. Conclusions: Our study demonstrates that few Dcx+ neuroblasts are proliferative in normal conditions, and that this population of proliferative neuroblasts is increased in response to stroke. We further show that CTX0E03 transplantation after stroke leads to the maintenance of this proliferative activity. Interestingly, the preservation of neuronal proliferative activity upon CTX0E03 transplantation is preceded and accompanied by a high rate of proliferating microglia. Our study suggests that microglia might mediate in part the effect of CTX0E03 transplantation on neuronal proliferation in ischemic stroke conditions. © 2012 Hassani et al.


News Article | December 5, 2016
Site: www.reuters.com

(Reuters) - Biotechnology company ReNeuron Group Plc said its experimental stem cell therapy helped some patients improve motor functions in their arms in a mid-stage study after being disabled by stroke.


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l4hbfj/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/34dzt6/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Loading ReNeuron Group collaborators
Loading ReNeuron Group collaborators